MCI (mild cognitive impairment). Mild cognitive disorder
Conditions
Interventions
Intervention 1: Intervention group: Zintoma capsules 250 mg three times a day for 2 months (Goldaru Pharmaceutical Company). Intervention 2: Control group: Zintoma placebo capsule 250 mg three times a
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Memory impairment that confirmed by another person Normal general cognitive function No defects in daily activities Normal visual and auditory ability Memory impairments should not be enough to classify a person with Alzheimer's disease
Exclusion criteria
Exclusion criteria: History of head trauma with loss of consciousness after injury, for example due to hypoxia History of significant cerebrovascular disease Pregnant or lactating women Prescribing other research drugs Concomitant use of cognitive-interfering drugs such as anticholinergic, anticonvulsants, anti-Parkinson drugs, stimulants, cholinergic drugs, antipsychotics, analgesics or antidepressants or anti-anxiety Use of cholinesterase inhibitors or memantine for the past 1 month Severe asthma or chronic obstructive pulmonary disease History of myocardial infarction in the last 3 months Mental retardation and Down syndrome Any history of seizures, active gastric ulcers, gallstones Cognitive impairment that can be attributed to conditions such as hypoxia, seizures, vitamin deficiencies, brain damage, meningitis, catabolic or endocrine disorders, mental retardation, brain tumors, or substance abuse Acute or chronic renal disease, liver or metabolic disorders, uncontrolled hypertension or diabetes mellitus History of active malignancy or prostate cancer in the last 24 months History of active gastric or duodenal ulcer during the last 3 months Any history of major psychiatric disorder including psychosis, major depression, bipolar disorder or alcohol or drug abuse Myocardial infarction or central nervous system infection Allergy to ginger, allergic reactions including dermatitis Possibility of surgical candidate Patients with coagulopathy and bleeding disorders or taking anticoagulants including warfarin (due to the antiplatelet effects of ginger and increased risk of bleeding) Patients with evidence of other neurodegenerative diseases or cardiovascular disease who are unable to complete the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical Dementia Rating (CDR) scale score. Timepoint: In weeks 4 and 8. Method of measurement: CDR questionnaire.;Mini-Mental State Examination (MMSE) score. Timepoint: In weeks 4 and 8. Method of measurement: MMSE questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects. Timepoint: In weeks 4 and 8. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyyed Mohammad Mousavi Mirzaei
Birjand University of Medical Sciences
Outcome results
None listed